Peking University Cancer Hospital & Institute clinical trials
Listed in the registry as: University, hospital or other organization.
The registry lists 266 studies whose lead sponsor is Peking University Cancer Hospital & Institute. 128 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 20, 2026.
Keep track of what changes. Save the Peking University Cancer Hospital & Institute studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesWhere
- China
- 213
Focus areas
Conditions Peking University Cancer Hospital & Institute leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 266. Browse all 266 →
- SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular CarcinomaNot yet recruitingNCT07882056Phase 2
- A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral MelanomaNot yet recruitingNCT07854522Phase 4
- Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + BevacizumabRecruitingNCT06141265Phase 2
- RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 ExpressionRecruitingNCT06420973Phase 2
- Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian CancerNot yet recruitingNCT07843303Phase 2
- Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide ProbesRecruitingNCT07848243Phase 2
- Perioperative Treatment of Hepatoid Adenocarcinoma of StomachRecruitingNCT06992362Phase 2
- Local Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma After Low Anterior Resection for Rectal CancerRecruitingNCT07833319Phase 2
- Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and SurgeryNot yet recruitingNCT07822906
- Retlirafusp Alfa Plus Targeted Therapy and Chemotherapy for Unresectable Colorectal Liver-Limited MetastasesNot yet recruitingNCT07815288Phase 2
- SLNB Combined With WLNB for Axillary De-escalation in Breast Cancer Patients With Abnormal Axillary NodesNot yet recruitingNCT07791771
- 89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian CancerNot yet recruitingNCT07790939Early Phase 1
- CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid TumorsRecruitingNCT05436093Not applicable
- NOMAD-GI: Molecular-guided Non-operative Management and Organ Preservation Strategy After Precision Therapy in Gastrointestinal CancersNot yet recruitingNCT07775859
- Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung CancerRecruitingNCT06768307Phase 2
- Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular ImagingRecruitingNCT06715020Not applicable
- MMP14(MT1-MMP) Targeting Bicyclic Peptide Probe for PET Imaging in Solid TumorsRecruitingNCT06719856
- 18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring ImmunotherapyRecruitingNCT07724535Phase 1/2
- Development and Validation of a Colorectal Cancer Diagnostic ModelNot yet recruitingNCT07692555
- SHR-A1904 in Advanced Colorectal Cancer: an Exploratory StudyNot yet recruitingNCT07700719Phase 2
- A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal MelanomaEnrolling by invitationNCT06424626Phase 1
- Fosrolapitant and Palonosetron for the Prevention of Antibody-drug Conjugate-induced Nausea and VomitingNot yet recruitingNCT07692451Phase 2
- Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI CancersNot yet recruitingNCT07656740
- Precision Medicine for Immunotherapy-Resistant Advanced Esophageal CancerNot yet recruitingNCT07653451Phase 2/3
- Safety and Efficacy of NOM and OPFS Versus RO for dMMR/MSI-H or POLE-Mutated Gastrointestinal CancersNot yet recruitingNCT07642323
- 68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid TumorsNot yet recruitingNCT07639801Not applicable
- Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung AdenocarcinomaNot yet recruitingNCT07622706Phase 2
- Abemaciclib Dose Escalation in Early High-Risk Breast Cancer Adjuvant TherapyNot yet recruitingNCT07599137Phase 4
- Iparomlimab Tolvorlimab as Neoadjuvant Immunotherapy for Locally Advanced Gastric Adenocarcinoma With Microsatellite Instability/Mismatch Repair DeficiencyNot yet recruitingNCT07595523Phase 2
- Clinical Application of CAIX-Targeted PET Imaging in TumorsRecruitingNCT07590310Early Phase 1
- 5T4 Targeting Nanobody Probe for PET Imaging in Solid TumorsNot yet recruitingNCT07589101Not applicable
- Al18F-HER2-BCH PET in Breast Patients Treated With ADC TherapyRecruitingNCT06909604Not applicable
- Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLCNot yet recruitingNCT07567326Phase 2
- Comparison of [68Ga]Ga-CTR-FAPI and 18F-FDG PET/MRI for Lymph Node Staging in Rectal CancerNot yet recruitingNCT07552207Not applicable
- Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular ImagingNot yet recruitingNCT07527806Phase 2
- Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid TumorsRecruitingNCT07529002
- Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast CancerNot yet recruitingNCT07470203
- PD-L1 Targeting Peptide Probe for PET Imaging of Solid TumorNot yet recruitingNCT07442292
- Nectin-4 Specific LMW PET Probe Imaging in Urothelial CarcinomaRecruitingNCT05321316Not applicable
- SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized StudyNot yet recruitingNCT07417241Phase 2
- A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line TreatmentRecruitingNCT07413042Phase 1
- Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-III Rectal CancerNot yet recruitingNCT07394192Phase 2
- Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT AloneNot yet recruitingNCT07381543Phase 2
- CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal CancerNot yet recruitingNCT07383285Phase 2
- A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical SurgeryRecruitingNCT06674252Not applicable
- Autologous Probiotics in Patients With Defunctioning Ileostomy Following LAR for Rectal CancerNot yet recruitingNCT07366047Not applicable
- Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRDNot yet recruitingNCT07357532Phase 2
- Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mgNot yet recruitingNCT07298148Phase 2
- Hand and Foot Bath for Taxane-Induced Peripheral NeurotoxicityNot yet recruitingNCT07344974Phase 4
- Standardized Management of Esophageal Fistula in Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07353541